SteinCares and Shilpa Biologicals Biosimilar Licensing
Analysis based on 15 articles · First reported Feb 25, 2026 · Last updated Feb 25, 2026
The licensing agreement between SteinCares and Shilpa Medicare===Shilpa Biologicals Private Limited is expected to positively impact the pharmaceutical and biotechnology markets, particularly in Latin America, by expanding access to cost-effective biosimilar treatments. This collaboration could lead to increased revenue and market share for both SteinCares and Shilpa Medicare.
SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Medicare===Shilpa Biologicals Private Limited (SBPL), a biopharmaceutical subsidiary of Shilpa Medicare, have announced a strategic licensing agreement. Under this agreement, SteinCares will gain exclusive rights to register, commercialize, and distribute a biosimilar across Latin America. SBPL will be responsible for product development and commercial manufacturing from its facility in Dharwad, India. This partnership marks SBPL's entry into the Latin American market and aims to expand patient access to cost-effective treatments, reinforcing SteinCares' leadership in biosimilars in the region. Both CEOs, Mitchell Waserstein of SteinCares and Sridevi Khambhampaty of Shilpa Medicare===Shilpa Biologicals Private Limited, expressed enthusiasm for the collaboration, highlighting its potential to create significant value for patients, healthcare systems, and their respective organizations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard